Education
About Us
Working with TipRanks
Follow Us
Clene (CLNN)
NASDAQ:CLNN
CLNN Stock Chart & Stats
$6.25
-$0.20(-3.40%)
At close: 4:00 PM EST
$6.25
-$0.20(-3.40%)
Day’s Range― - ―
52-Week Range$2.28 - $13.50
Previous CloseN/A
Volume48.08K
Average Volume (3M)239.17K
Market Cap
$64.59M
Enterprise Value$75.35M
Total Cash (Recent Filing)$7.92M
Total Debt (Recent Filing)$21.31M
Price to Earnings (P/E)―
Beta1.59
Next Earnings
Mar 30, 2026EPS Estimate
-0.55Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.85
Shares Outstanding10,333,980
10 Day Avg. Volume80,326
30 Day Avg. Volume239,167
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-4.17
Price to Sales (P/S)107.97
P/FCF Ratio-1.73
Enterprise Value/Market Cap1.17
Enterprise Value/Revenue352.11
Enterprise Value/Gross Profit428.14
Enterprise Value/Ebitda-2.84
Forecast
1Y Price Target
$30.40Price Target Upside386.40% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-2.3
Revenue Forecast (FY)$191.00K
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsCNM-Au8's clinical studies have enrolled the most heterogenous group of patients, with the least scrutinous exclusion criterion, and still demonstrated meaningful results.
Financial OpportunitiesAcceptance of the NDA by the FDA will enable the company to access $130.8 million in additional funding.
Regulatory ApprovalCNM-Au8 has Orphan Drug Designation which should qualify for Priority Review, potentially leading to a faster approval process.
Bears Say
Clene News
CLNN FAQ
What was Clene’s price range in the past 12 months?
Clene lowest stock price was $2.28 and its highest was $13.50 in the past 12 months.
What is Clene’s market cap?
Clene’s market cap is $64.59M.
When is Clene’s upcoming earnings report date?
Clene’s upcoming earnings report date is Mar 30, 2026 which is in 92 days.
How were Clene’s earnings last quarter?
Clene released its earnings results on Nov 13, 2025. The company reported -$0.85 earnings per share for the quarter, missing the consensus estimate of -$0.58 by -$0.27.
Is Clene overvalued?
According to Wall Street analysts Clene’s price is currently Undervalued.
Does Clene pay dividends?
Clene does not currently pay dividends.
What is Clene’s EPS estimate?
Clene’s EPS estimate is -0.55.
How many shares outstanding does Clene have?
Clene has 10,333,980 shares outstanding.
What happened to Clene’s price movement after its last earnings report?
Clene reported an EPS of -$0.85 in its last earnings report, missing expectations of -$0.58. Following the earnings report the stock price went down -22.423%.
Which hedge fund is a major shareholder of Clene?
Currently, no hedge funds are holding shares in CLNN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Clene Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$30.40 (386.40% Upside)
$30.40 (386.40% Upside)
Blogger Sentiment
Bullish
CLNN Sentiment 100%
Sector Average 63%
Sector Average 63%
Hedge Fund Trend
Decreased
By 43.0 Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.2%
Last 30 Days ▼ 3.1%
Last 30 Days ▼ 3.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
23.03%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-29.33%
Trailing 12-Months
Company Description
Clene
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; ongoing Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a planned Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company's products also include CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to accelerate wound healing; CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease, such as COVID-19 and to provide immune support for symptom resolution; and CNM-PtAu7, a gold-platinum CSN therapeutic for oncology applications. It also markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.
CLNN Stock 12 Month Forecast
Average Price Target
$30.40
▲(386.40% Upside)
Technical Analysis
Dyadic International
―
Akari Therapeutics
―
Estrella Immunopharma
―
AN2 Therapeutics, Inc.
―
CAMP4 Therapeutics Corporation
―
Ownership Overview
72.21% Insiders
2.07% Mutual Funds
3.41% Other Institutional Investors
20.77% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---